Abstract:
A content provider computing device that transmits content to receivers at scheduled air times receives information regarding conditions relating to the transmissions. The computing device also receives data regarding content that a receiver will record. The computing device evaluates the information and compares it with the data to determine that there is a risk of interrupted transmission. As a result, the computing device transmits the content to the receiver prior to the scheduled air time. The conditions may include weather conditions, power outage conditions, and/or any other conditions that may affect transmission. In various implementations, the computing device may include content controls prior to transmission that prevent the content from being accessed prior to specified times. In some cases, the content control may prevent all access. In other cases, the content control may prevent some kinds of access to the instance of content prior to particular times and allow others.
Abstract:
In embodiments disclosed herein, television recording schedules are automatically adjusted in a digital video recording system. In at least one embodiment, the digital video recording system receives a first request to record a first program at the digital video recording system and a second recording request to record a second program at the digital video recording system. The system determines that there are insufficient resources to fulfill both the first and second recording requests. The system may set an open recording request for at least one of the first and second programs, which seeks additional scheduling data corresponding to at least one of the programs. Subsequent additional data may be received to fulfill the open recording request. In some embodiments, recording requests may be automatically rescheduled to more optimal recording times.
Abstract:
GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
Abstract:
GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
Abstract:
Novel compounds composition capable of inhibiting TNFα and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.
Abstract:
Novel compounds composition capable of inhibiting TNFα and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.
Abstract:
The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.
Abstract:
Systems and methods are operable to retrieve at least a portion of a missed media content event. An exemplary embodiment detects an occurrence of a failed recording of at least a portion of a media content event of interest; transmits a notification of the detected occurrence of the failed recording of the at least the portion of the media content event of interest from a media device to a replacement content device; and receives, at the media device, at least a portion of missed media content corresponding to at least the portion of the media content event of interest that failed to record.
Abstract:
A content provider computing device that transmits content to receivers at scheduled air times receives information regarding conditions relating to the transmissions. The computing device also receives data regarding content that a receiver will record. The computing device evaluates the information and compares it with the data to determine that there is a risk of interrupted transmission. As a result, the computing device transmits the content to the receiver prior to the scheduled air time. The conditions may include weather conditions, power outage conditions, and/or any other conditions that may affect transmission. In various implementations, the computing device may include content controls prior to transmission that prevent the content from being accessed prior to specified times. In some cases, the content control may prevent all access. In other cases, the content control may prevent some kinds of access to the instance of content prior to particular times and allow others.
Abstract:
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.